Email Updates

You are here

Webinar & Meeting Reports

  • July 1, 2020 to July 10, 2020

    In early July, the world’s largest gathering on HIV/AIDS went virtual for the first time. AIDS 2020:Virtual, the 23rd edition of the International AIDS Conference, offered the latest scientific breakthroughs on HIV, opportunities for advocates to come together to sharpen their agenda and new to this year, a special day-long meeting devoted to COVID-19.

  • June 22, 2020 to August 28, 2020

    This 10-week interactive and online course will help researchers and clinical trial stakeholder to apply the Good Participatory Practice (GPP) Guidelines in their unique settings. In this unprecedented time, sustaining effective partnerships is more crucial than ever before. This course provides a personalized learning experience, global knowledge, tools to advance GPP implementation in diverse contexts and access to GPP experts and professional networks. For more information, send an email to gpponlinecourse@avac.org.

  • June 9, 2020

    The COVID-19 pandemic has accelerated the research process. Sponsors, researchers, ethics committee members and other stakeholders are moving faster than ever to move effective products through the research pipeline. The pace of the research is also changing how stakeholder engagement is conducted. On Tuesday, June 9, speakers discussed the experience of conducting stakeholder engagement during the Ebola crisis in West Africa. They also explored some of the ethical challenges to conducting research in a public health emergency.

  • June 1, 2020 to October 30, 2020

    The HIV2020 Conference has been reimagined as a series of virtual convenings that will take place June through October of this year.

  • May 22, 2020

    On Friday, May 22, the HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men.

  • May 18, 2020

    May 18 is HIV Vaccine Awareness Day (HVAD), a day when partners around the world join to celebrate the people, partnerships and science pushing ever closer to a safe, efficacious and accessible vaccine against HIV. Check out AVAC's dedicated HVAD 2020 page, which includes a toolkit, details on related webinars to support advocacy and action and more.

  • May 13, 2020

    Six months? A year? Longer? Never? How long until there’s a vaccine against COVID-19? How is COVID vaccine research moving so quickly? How do HIV vaccine and COVID-19 vaccine research relate and inform each other? On Wednesday, May 13, we conducted a webinar with Jon Cohen, one of the leading journalists covering both HIV and COVID.

  • May 7, 2020

    On Thursday, May 7, AVAC held a webinar, The Power–and Pitfalls–of Modeling for COVID-19 and HIV, to discuss current COVID-19 models, and the benefits and limitations of mathematical models as they apply to both COVID-19 and HIV prevention.

  • April 9, 2020

    Professor Sinead Delany-Moretlwe of Wits RHI talks with community engagement practitioners from trial site communities across Africa on how HIV clinical trials will be affected by the global response to COVID-19.

  • April 2, 2020

    On Thursday, April 2, AVAC held it second webinar on COVID-19 and its relationship to HIV. Dr. Mark Feinberg, CEO of IAVI, shared experiences and lessons from Ebola and HIV vaccine development that might be applied to COVID-19 vaccine development. Dr. Feinberg was joined by Dr. Helen Rees of Wits RHI to discuss the history and role of the Coalition for Epidemic Preparedness Innovations (CEPI), which supports vaccine development against emerging infectious diseases, including COVID-19.

Pages